| Vincenzo Gianfrancesco, | |
|
1970 Pawtucket Ave, East Providence, RI 02914-1718 | |
| (401) 438-1166 | |
| Not Available |
| Full Name | Vincenzo Gianfrancesco |
|---|---|
| Gender | Male |
| Speciality | Optometry |
| Experience | 9 Years |
| Location | 1970 Pawtucket Ave, East Providence, Rhode Island |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1447633060 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 152W00000X | Optometrist | ODTG00620 (Rhode Island) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Modern Eyes Llc | 9638425119 | 2 |
News Archive
Endo Pharmaceuticals has submitted a complete response to the U.S. Food and Drug Administration (FDA) following the company's receipt of a Complete Response letter in October 2009 related to the New Drug Application (NDA) submission for FORTESTA™ (testosterone) 2% gel. The company's Class 2 resubmission is the next step in its intention to offer FORTESTA as a treatment option in the United States for men diagnosed with low testosterone (Low T), also known as hypogonadism. The FDA's review period for Class 2 resubmissions typically is six months.
European surveillance data show a 10% decrease in newly reported hepatitis C cases between 2016 and 2017. However, with more than 31 000 recorded cases in 2017, diagnoses remain at a high level in the European Union and European Economic Area.
KHN reports that Minority Leader John Boehner is taking issue with "the drug industry's decision to agree to $80 billion in concessions to the White House."
Researchers in the UK report that much of the potential beneficial impact of the November 2020 English National lockdown on the coronavirus disease 2019 (COVID-19) epidemic was likely undermined in many areas due to increased socializing in the days running up to its implementation.
Boston Scientific Corporation today announced U.S. Food and Drug Administration (FDA) approval for LATITUDE 6.0, a software upgrade to the Company's LATITUDE® Patient Management system. The LATITUDE system enables physicians to remotely monitor patients with implantable cardiac devices. The upgrade provides enhanced functionality, including the ability to view an expanded history of a patient's remote follow-up data.
› Verified 2 days ago
| Provider Name | Modern Eyes Llc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1265938179 PECOS PAC ID: 9638425119 Enrollment ID: O20180713001712 |
News Archive
Endo Pharmaceuticals has submitted a complete response to the U.S. Food and Drug Administration (FDA) following the company's receipt of a Complete Response letter in October 2009 related to the New Drug Application (NDA) submission for FORTESTA™ (testosterone) 2% gel. The company's Class 2 resubmission is the next step in its intention to offer FORTESTA as a treatment option in the United States for men diagnosed with low testosterone (Low T), also known as hypogonadism. The FDA's review period for Class 2 resubmissions typically is six months.
European surveillance data show a 10% decrease in newly reported hepatitis C cases between 2016 and 2017. However, with more than 31 000 recorded cases in 2017, diagnoses remain at a high level in the European Union and European Economic Area.
KHN reports that Minority Leader John Boehner is taking issue with "the drug industry's decision to agree to $80 billion in concessions to the White House."
Researchers in the UK report that much of the potential beneficial impact of the November 2020 English National lockdown on the coronavirus disease 2019 (COVID-19) epidemic was likely undermined in many areas due to increased socializing in the days running up to its implementation.
Boston Scientific Corporation today announced U.S. Food and Drug Administration (FDA) approval for LATITUDE 6.0, a software upgrade to the Company's LATITUDE® Patient Management system. The LATITUDE system enables physicians to remotely monitor patients with implantable cardiac devices. The upgrade provides enhanced functionality, including the ability to view an expanded history of a patient's remote follow-up data.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Vincenzo Gianfrancesco, 1970 Pawtucket Ave, East Providence, RI 02914-1718 Ph: () - | Vincenzo Gianfrancesco, 1970 Pawtucket Ave, East Providence, RI 02914-1718 Ph: (401) 438-1166 |
News Archive
Endo Pharmaceuticals has submitted a complete response to the U.S. Food and Drug Administration (FDA) following the company's receipt of a Complete Response letter in October 2009 related to the New Drug Application (NDA) submission for FORTESTA™ (testosterone) 2% gel. The company's Class 2 resubmission is the next step in its intention to offer FORTESTA as a treatment option in the United States for men diagnosed with low testosterone (Low T), also known as hypogonadism. The FDA's review period for Class 2 resubmissions typically is six months.
European surveillance data show a 10% decrease in newly reported hepatitis C cases between 2016 and 2017. However, with more than 31 000 recorded cases in 2017, diagnoses remain at a high level in the European Union and European Economic Area.
KHN reports that Minority Leader John Boehner is taking issue with "the drug industry's decision to agree to $80 billion in concessions to the White House."
Researchers in the UK report that much of the potential beneficial impact of the November 2020 English National lockdown on the coronavirus disease 2019 (COVID-19) epidemic was likely undermined in many areas due to increased socializing in the days running up to its implementation.
Boston Scientific Corporation today announced U.S. Food and Drug Administration (FDA) approval for LATITUDE 6.0, a software upgrade to the Company's LATITUDE® Patient Management system. The LATITUDE system enables physicians to remotely monitor patients with implantable cardiac devices. The upgrade provides enhanced functionality, including the ability to view an expanded history of a patient's remote follow-up data.
› Verified 2 days ago
Dr. Stephen A Remsbecker, OD Optometrist Medicare: Accepting Medicare Assignments Practice Location: 224 Waterman Ave E, East Providence, RI 02914 Phone: 401-438-2445 Fax: 401-438-2447 | |
Dania Khan, Optometrist Medicare: Medicare Enrolled Practice Location: 400 Warren Ave, East Providence, RI 02914 Phone: 401-438-4447 | |
Dr. Robert W. Hill Iii, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 400 Warren Ave, East Providence, RI 02914 Phone: 401-438-4447 Fax: 401-438-0160 | |
Dr. Lyn-marie Behmke, OD Optometrist Medicare: Accepting Medicare Assignments Practice Location: 2728 Pawtucket Ave, East Providence, RI 02914 Phone: 401-434-5532 Fax: 401-435-5405 | |
Brown Vision Care, Inc Optometrist Medicare: Medicare Enrolled Practice Location: 400 Warren Ave, East Providence, RI 02914 Phone: 401-438-4447 Fax: 401-438-4447 | |
Dr Lyn-marie Behmke Od Optometrist Medicare: Medicare Enrolled Practice Location: 2728 Pawtucket Ave, East Providence, RI 02914 Phone: 401-434-5132 Fax: 401-435-5405 | |
Dr. April Lynn Brown, OD Optometrist Medicare: Accepting Medicare Assignments Practice Location: 400 Warren Ave, East Providence, RI 02914 Phone: 401-438-4447 |